RAPT Therapeutics, Inc.

NasdaqGM:RAPT Rapport sur les actions

Capitalisation boursière : US$37.4m

RAPT Therapeutics Dividendes et rachats

Dividende contrôle des critères 0/6

RAPT Therapeutics n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

-27.3%

Rendement des rachats

Rendement total pour l'actionnaire-27.3%
Rendement futur des dividendes0%
Croissance des dividendesn/a
Prochaine date de paiement du dividenden/a
Date ex-dividenden/a
Dividende par actionn/a
Ratio de distributionn/a

Mises à jour récentes sur les dividendes et les rachats

Pas de mise à jour

Recent updates

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Nov 10
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21
Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23
The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19
Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de RAPT ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de RAPT ont augmenté.


Rendement des dividendes par rapport au marché

RAPT Therapeutics Rendement des dividendes par rapport au marché
Comment le rendement du dividende de RAPT se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (RAPT)n/a
25% du marché (US)1.4%
25% du marché (US)4.3%
Moyenne du secteur (Biotechs)2.3%
Analyste prévisionnel (RAPT) (jusqu'à 3 ans)0%

Dividende notable: Impossible d'évaluer le rendement des dividendes de RAPT par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de RAPT par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.


Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de RAPT afin de déterminer si les dividendes versés sont couverts par les bénéfices.


Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car RAPT n'a signalé aucun versement.


Découvrir des entreprises qui versent des dividendes élevés